A phase I evaluation of the effect of curcumin on dose‐limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors

Curcumin inhibits UDP‐glucuronyltransferases, a primary metabolic pathway for cancer chemotherapeutic agents like irinotecan. Concurrent administration of both agents may exacerbate irinotecan toxicity. We conducted this phase I study to determine the safety of concurrent curcumin and irinotecan adm...

Descripción completa

Detalles Bibliográficos
Autores principales: Gbolahan, Olumide B., O’Neil, Bert H., McRee, Autumn J., Sanoff, Hanna K., Fallon, John K., Smith, Philip C., Ivanova, Anastasia, Moore, Dominic T., Dumond, Julie, Asher, Gary N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099132/
https://www.ncbi.nlm.nih.gov/pubmed/35157783
http://dx.doi.org/10.1111/cts.13250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099132/
https://www.ncbi.nlm.nih.gov/pubmed/35157783
http://dx.doi.org/10.1111/cts.13250

Ejemplares similares